Antithrombin III Deficiency
Conditions
Keywords
AT-III deficiency, AT-III concentrate, Bleeding disorders, Blood disorders
Brief summary
To assess the safety, pharmacokinetics and efficacy of a plasma-derived AT-III concentrate in the treatment of subjects with congenital AT-III deficiency.
Detailed description
This study will be a prospective, unblinded, non-randomized, open-label, multi-center Phase II/III study with 2 segments, i.e. a PK evaluation (Segment I), and an assessment of prophylaxis in surgical interventions and pregnancy/delivery, (Segment II). During the PK segment (Segment I), the subjects would remain on their current anticoagulation therapy except for subjects on heparin therapy where a wash-out period of at least 5 half-lives would be required. In total, 15 subjects with congenital ATIII Deficiency will be enrolled for the PK assessment (Segment I). For Segment II, fifteen episodes will be treated. Recruitment of individual subjects with high risk for venous thrombosis for Segment II of this study is necessary because of the rarity of Antithrombin deficiency in the population.
Interventions
DRUGPlasma-derived AT-III concentrate
Segment I: A single dose IV infusion of 50 IU/kg of ATIII-DAF/DI will be administered to each patient. Segment II: A single dose or multiple doses depending on the subject's ATIII plasma levels and patient's specific treatment plan.
Sponsors
Grifols Biologicals, LLC
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Congenital ATIII deficiency documented by determination of plasma levels of ATIII off all therapies. Specifically, the baseline levels of ATIII activity should be equal to or less than 60%. * Age \>12 years with a body weight of no less than 30 kg. * Have not participated in another investigational study for at least 30 days. For Segment II, enrollment requires a pregnancy/delivery or a surgical procedure (it should be a major surgery although data from a minor surgery will also be collected). * Documented personal history of major thromboembolic or thrombotic event. * Male or female * HIV, HBV, HCV, HAV and PARVO B19 status known prior to entry. * The subject is willing to comply with all aspects of the protocol, including blood sampling, for the duration of the study. * The subject has signed an informed consent form (if at least 18 years old), or the subject's parent or legal guardian has signed the informed consent form. Subjects below the age of 18 years will also be asked to sign an assent form. All consent and assent forms must be approved in advance by the Institutional Review Board of the investigator's institution. * Patients with heparin-associated thrombocytopenia who require anticoagulation with non-heparin containing drugs will be eligible if they can be safely transitioned during the washout period for the Segment I PK study. * If pregnant, a woman must be Parvo B19 IgG antibody positive.
Exclusion criteria
* Acquired deficiency of ATIII. * Receiving concomitant treatment for thrombophilic disorders other than ATIII deficiency. * Inability or unwillingness to comply with the protocol requirements. * History of anaphylactic reaction(s) to blood or blood components. * Allergies to excipients. * Liver function tests \>/= 2.5 X ULN * Serum creatinine \>1.2 X ULN. * Urine \>/= 2+ protein with urine dipstick test. * The subject is known to have abused alcohol or illicit drugs within the past 12 months. * The subject is unlikely to adhere to the protocol requirements of the study or is likely to be uncooperative or unable to provide a storage serum sample at the screening visit. * Patients on heparin-treatment who, for clinical reasons, cannot safely be discontinued from heparin therapy during the PK segment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary objectives of this clinical study are to: | 2 years |
| Assess the pharmacokinetic (PK) profile of AT-III in congenital AT-III deficient patients | 1 year |
| To measure the in vivo recovery and half-life of AT-III. | 1 year |
| To assess the clinical safety and tolerability of AT-III-DAF/DI. | 1 year |
Secondary
| Measure | Time frame |
|---|---|
| To assess clinical efficacy by preventing thromboembolic or thrombotic events (prophylaxis) in individuals with congenital AT-III deficiency who are undergoing surgical procedures or who are pregnant and undergoing parturition. | 1 year |
Outcome results
None listed